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10.1586/14750708.3.3.403 © 2Background: Breast cancer is the most commonly diagnosed neoplasia in women after 
nonmelanoma skin tumors. Unfortunately, present-day diagnostic methods are unable to 
identify the presence of a cancer until it has been developing for several years. Currently, 
ductal lavage seems to represent a new method of reaching an early diagnosis of breast 
cancer. Materials & methods: This study analyzed 30 patients with ages ranging from 
40 to 55 years; and in 26 of these patients, we were able to obtain a sufficient quantity of 
material for cytological and biomolecular analysis. Results & conclusion: We propose an 
easy, reproducible method that makes it possible to obtain a detailed map of the nipple, in 
order to re-identify the duct orifice and take a series of repeated samples from it over a 
period of time. This procedure is a promising screening and translational research tool 
since it provides the quantity and quality of ductal fluid required for subsequent 
cytological and biomolecular analyses.Breast cancers are the most commonly diagnosed
neoplasias in women after nonmelanoma skin
tumors and the second cause of death from can-
cer in this population [1]. Unfortunately, present-
day diagnostic methods such as mammography,
magnetic resonance, ultrasound and nuclear
medicine, are unable to identify the presence of a
cancer until it has been developing for
several years and has reached a size which can be
seen as an anomalous mass within the normal
breast tissue. It is therefore necessary to find a
new way of reaching an early diagnosis of breast
carcinoma – ductal lavage would seem to fulfill
this hope [2,3].
It has already been established that most can-
cers of the breast originate in the epithelial cells
covering the ducts of the mammary gland [4]; the
lavage of these ducts is a fairly new and simple
method of collecting these cells; it is not particu-
larly invasive and above all makes it possible to
extract a much larger quantity of material for
analysis (an average of 13,500 cells/duct) than
that resulting from traditional nipple aspiration
(an average of 100 cells/duct) [5]. The sample
obtained with this new method consists of ductal
fluid, which is mainly made up of proteinaceous
secretions of the ductal system and of ductal
cells; the fluid thus obtained provides informa-
tion not only about cell events, but also about
the dynamic secretory process of the breast [6]
and is therefore to be considered an efficient bio-
logical marker for evaluation of risk and the early
diagnosis of breast carcinoma. Unlike other diag-
nostic techniques, ductal lavage makes it possible
to trace premalignant and/or malignant cells by
means of the re-examination of the same duct
over time [7,8]. This procedure might therefore be
useful for the selection of women at high risk
who would benefit by more careful monitoring
and/or more individual preventive measures [9,10].
Currently, very little is known about the best
methods for the reproducible identification of
the duct itself. The aim of this study is to try to
find a more efficient method of identifying the
ductal orifice in patients at high risk for breast
cancer and patients who had previously under-
gone radical breast surgery.
Materials & methods
A total of 30 patients between the ages of
40–55 years were selected for a preliminary study
on ductal lavage conducted in the Molecular
Unit of the Department of Oncology of Palermo
University (Palermo, Italy). 
Patients were required to have the following
requisites: be at high risk for the disease (Gail
index > 1.7; previous history of breast cancer;
genetic mutation of the BRCA1/2 genes) have
had a mammography and medical examination
with negative results during the 12 months prior
to lavage. Women who had previously under-
gone radical breast surgery or mastectomy for a
prior breast cancer, but only the controlateral
breast, were studied. Patients who had received
chemotherapy or tamoxifen/selective estrogen-
receptor modulator (SERM) treatment, or who
were pregnant or breastfeeding [5,6] were not con-
sidered eligible for ductal lavage. Furthermore,006 Future Drugs Ltd  ISSN 1475-0708 Therapy (2006)  3(3), 403–407 403
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Figure 2. Insertion opatients with mucous or purulent secretions
were excluded from the study, since the dense
secretion in the former cases causes cannulation
difficulties, while in the latter patients cannula-
tion may lead to infection subsequent to the
injection of the physiological fluid into the
ducts. Moreover, women with congenital nipple
introflexion were also excluded from the study.
Ductal lavage involves three basic steps: nipple
aspiration; cannulation and lavage of the duct;
and cytological and biomolecular interpretation
of the sample. A local anesthetic containing lido-
caine is applied around the nipple approximately
30 min before the start of the procedure. The
nipple aspiration step involves the identification
of the secreting duct or ducts. Ductal lavage can
only be performed on naturally secreting ducts,
since it is extremely difficult to cannulize a non-
secreting duct; if necessary, a suction pump may
be placed on the nipple or the breast can be mas-
saged to facilitate the emission of the ductal
secretions; this study utilized the second method. 
After identifying the secreting duct, cannula-
tion and lavage are performed. For this, we used a
set of dilators of gradually increasing diameters
(Sterylab S.p.A) until the ductal orifice was wide
enough to insert a microcatheter linked up to a
two-way hydraulic system (Figures 1 & 2), with a
connecting stopcock (BRAUN, Melsungen AG
D-34209) between the two tubes, one for the
entry of the lavage solution and the other for it’s
exit. After inserting the microcatheter into the
duct to a depth of approximately 1.5 cm, 5–10 ml
of lavage solution (physiological saline) was grad-
ually injected at a pace of 2 ml at a time. The
breast was massaged after each step of the infusion
to facilitate the exfoliation of ductal epithelial
cells. A further breast massaged was performed at
the end of this insufflation stage and then pro-
ceeded to the aspiration stage for the collection of
ductal fluid to be used for the subsequent
cytological and biomolecular investigation.
It is important to note the advantage of using
the two-way stopcock system, which makes it
possible for the physician to perform consecu-
tive, step-by-step insufflation and aspiration of
small quantities of fluid, since our group
observed that when more than 1–2 ml of saline
solution was injected at once, several patients
complained of breast tension and pain. Further-
more, with the rapid, consecutive insufflation
and aspiration of small quantities of fluid, it is
possible to prevent the tissues from reabsorbing
the insufflated fluid. The two-way stopcock also
makes it possible to leave the two syringes (one
for the entrance and the other one for the exit of
the fluid) in place simultaneously, using them
alternately and thus avoiding discomfort for the
patient caused by repeated attachment and
removal of the syringe from the microcatheter,
which may cause pain in the nipple area.
The above-described procedure can be applied
to several secreting ducts, either of the same or of
both breasts; it is extremely important at this
point to be able to accurately identify premalig-
nant and/or malignant cells from the same duct
over time. For this reason, a fundamental step in
ductal lavage regards the precise location of the
cannulated duct. In order to solve this problem,
our group has arranged a system of Cartesian
axes linked to a goniometric system; the latter
was subdivided into four quadrants identified as: 
Figure 1. Microcatheter system.
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Figure 4. • Upper inside quadrant: UIQ
• Lower inside quadrant: LIQ
• Upper outside quadrant: UOQ (Figure 3)
This location system is applied to the breast
and the exact position of the duct is entered on a
grid where it is given a reference number and let-
ter and then photographed in order to document
the duct position (Figure 4).
Results
In four (13%) of the 30 selected cases, cannulation
proved to be impossible because of a slight ductal
secretion and of the reduced size of the duct itself.
From one 1–3 ml of material sufficient for cyto-
logical and biomolecular analysis was obtained
from 26 patients. By means of the Cartesian
localization method, we managed to identify
secreting ducts in 14 out of 26 patients on the
UIQ within a range of 280–300° and in the
remaining 12 out of 26 patients on the LOQ from
120–170°. The relative ease of the technique and
the simplicity of identifying the secreting duct
made it possible to repeat the same analysis several
times, thus guaranteeing the quality of the samples
used in the study. The method did not lead to any
complications or present any particular difficulties.
Discussion
Ductal lavage is only slightly invasive and is
extremely useful for the in vivo sampling of duc-
tal epithelial cells. This procedure may prove to
greatly assist in the identification of occult
malignant lesions in women at high risk of devel-
oping a breast cancer and may possibly become a
valid method of risk assessment and therefore of
early diagnosis [10].
Our method provides a detailed map of the
nipple which offers the repeated identification of
the ductal orifice involved and the subsequent
resampling of the same duct over time, which is
absolutely essential if ductal lavage is to become
a valid tool for preventive screening. In addic-
tion, the application of our technique does not
require the injection of a small quantity of anes-
thetic intraductally, allowing for a higher recov-
ery of cells and protein and a decrease in the
amount of pain experienced by patients. Ductal
lavage is often performed in women with non-
spontaneous secretion where the identification
of the secreting duct is reduced to 10–13%.
This procedure is also a promising transitional
research tool, since it provides a large quantity of
high-quality material needed for the subsequent
cytological and biomolecular analyses [11].
The ductal fluid obtained by means of ductal
lavage is examined by one or more cytologists
who establish the number and morphology of
the cells present in the sample, subdividing spec-
imens into five categories as follows: inadequate
diagnostic sample (fewer than ten epithelial
cells); sample containing benign tumor cells;
sample containing cells with intermediary aty-
pia; sample containing cells with severe atypia;
sample containing malignant cells [12].
There is considerable interest at present
regarding the integration of morphological inter-
pretations with the assessment of biomolecular
markers. Studies involving a large number of
molecular markers are now underway and the
accurate characterization of these is undoubtedly
of great importance, since they do not present
Figure 3. System of Cartesian axes 
linked to a goniometric system.405
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Evron and colleagues have studied the possi-
bility of identifying the presence of breast tumor
cells in ductal fluid by means of methylation-
specific-polymerase chain reaction (MSP) [9].
The authors have analyzed the methylation sta-
tus of the genes Cyclin D2, RAR-β and TWIST
in a series of 56 samples of ductal fluid from
women considered as clinically healthy. These
genes were proven to be methylated in 30% of
breast tumors, which does not occur in healthy
breast tissues. Of the 56 cases, six were cytologi-
cally classified as malignant or with severe atypia;
in 66% the three genes examined were methyl-
ated; most of the samples (50 samples) contained
cells with intermediary or benign atypia and
there was methylation in 11% of the cases. These
data suggest that methylation might be an early
event in the development of a breast cancer and
are important since this status can be reverted
with the use of dealkylating agents [14].
Isaacs and colleagues have assessed the pres-
ence of loss of heterozygosity (LOH) in the
BRCA1 and FHIT genes and of alterations of the
D310 microsatellite marker and in the mitochon-
drial DNA (mtDNA) in 26 samples of ductal
fluid obtained by means of ductal lavage in 14
women with known BRCA1 status (nine out of
14 women presented BRCA1 mutations, five out
of 14 had no mutations) but with no clinical
signs of neoplastic breast lesions. The authors
found that LOH occurring in several important
BRCA1 sites is an early event occurring in
women with mutations and may also be found in
nonmalignant cells. Furthermore, they found
alterations of the mtDNA in the D310 microsat-
ellite marker in 30% of the cases. These two
results taken together suggest that the study of
LOH at the BRCA1 gene and of mtDNA genetic
alterations in samples of ductal fluid might
become an important tool for the early diagnosis
of breast cancer to be associated with more
traditional screening methods [15].
Other authors have found instability in chro-
mosomes 1, 8, 11 and 17 (using Interphase Flu-
orescence in situ Hybridization) in 71% of
ductal fluid samples from patients with malig-
nant breast lesions and in 11% of samples from
patients with benign breast lesions [16]. Other
authors have observed the frequent loss of the
long arm of chromosome 16 (16q) and of the
short arm of chromosome 17 (17p) by means of
Comparative Genomic Hybridization, suggest-
ing that the alterations of genes in these chromo-
somal regions may play an early role in the
carcinogenesis of breast cancers [17].
In conclusion, ductal lavage is an extremely
new method for the sampling of breast ductal
cells; furthermore, the possibility of being able to
identify a previously examined duct means that
the method might become an extremely useful
screening tool. The future identification of new
molecular markers in ductal fluid could lead to a
great improvement in methods of early diagnosis
of breast carcinoma, in the study of breast car-
cinogenesis and in the monitoring of therapeutic
response. Unfortunately, no one has yet devel-
oped an inexpensive reproducible technique to
add and/or replace traditional cytology for these
specimens. Further studies, including the analysis
of a major number of cases and considering a list
of probably markers, are needed in order to reach
a more complete understanding of these aspects.
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